Premium
Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre
Author(s) -
Christensen Amalie P.,
Boegevig Soeren,
Christensen Mikkel B.,
Petersen Kasper M.,
Dalhoff Kim P.,
Petersen Tonny S.
Publication year - 2018
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12902
Subject(s) - aripiprazole , medicine , danish , drug , population , sedation , pediatrics , psychiatry , anesthesia , schizophrenia (object oriented programming) , environmental health , linguistics , philosophy
Abstract The aim of this study was to characterize the clinical signs and symptoms of exposures to aripiprazole overdoses. We retrospectively identified all aripiprazole exposures reported to the Danish Poison Information Centre ( DPIC ) from June 2007 to May 2015. Information concerning demographics, ingested dose and symptoms was extracted from the DPIC database and medical records. Information on death and admission to hospital was obtained from Danish national registers. We analysed 239 cases, 86 concerning single‐drug exposures to aripiprazole, and 153 cases where aripiprazole had been taken with at least one other substance (mixed‐drug). The median ingested aripiprazole dose was 105 mg ( IQR : 50‐1680 mg) in the single‐drug exposure group and 120 mg ( IQR : 60‐225 mg) in the mixed‐drug exposure group . The most commonly reported symptom was light sedation, reported in 63% of the single‐drug group and 50% of the mixed‐drug exposure group. There were no malignant arrhythmias or ECG abnormalities after single‐drug exposures. No deaths were recorded in relation to the intake. We found a long‐term mortality rate of 13 deaths per 1000 person‐years (95% CI : 7; 23 per 1000 person‐years), which is significantly higher than in an age‐ and gender‐matched background population. In conclusion, we found that aripiprazole overdoses had few and mild symptoms predominantly related to the sedative properties. We detected a benign cardiovascular safety profile and no new safety concerns. Our findings may support an increased threshold of 300 mg for hospital admission after a single‐drug exposure with aripiprazole and symptoms not worse than light sedation.